Among patients with ongoing, uncontrolled hypertension in spite of treatment with indapamide, amlodipine, or olmesartan, the addition of a single dose of investigative zilebesiran has, at 3 months,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
